Woodward Diversified Capital LLC Buys New Stake in Boston Scientific Corporation $BSX

Woodward Diversified Capital LLC bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 1,906 shares of the medical equipment provider’s stock, valued at approximately $205,000.

A number of other institutional investors also recently made changes to their positions in BSX. GAMMA Investing LLC raised its stake in Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after purchasing an additional 3,932 shares during the last quarter. Bank of New Hampshire raised its position in shares of Boston Scientific by 552.0% in the second quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after buying an additional 16,699 shares during the last quarter. NS Partners Ltd lifted its stake in shares of Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after buying an additional 5,704 shares during the period. MRA Advisory Group acquired a new stake in Boston Scientific during the second quarter worth approximately $273,000. Finally, Neville Rodie & Shaw Inc. grew its stake in Boston Scientific by 95.9% in the 2nd quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider’s stock worth $4,883,000 after acquiring an additional 22,255 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on BSX. Needham & Company LLC reissued a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a research note on Wednesday. Robert W. Baird raised their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research note on Wednesday. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a report on Monday, July 21st. Canaccord Genuity Group increased their price objective on shares of Boston Scientific from $131.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Barclays raised their target price on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research report on Thursday. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Boston Scientific has a consensus rating of “Buy” and an average price target of $120.79.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the firm’s stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director directly owned 18,479 shares of the company’s stock, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the business’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock valued at $17,972,457 in the last quarter. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 0.5%

BSX opened at $96.36 on Friday. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The firm has a 50 day moving average price of $103.10 and a 200 day moving average price of $102.06. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company has a market cap of $142.78 billion, a PE ratio of 57.36, a price-to-earnings-growth ratio of 2.31 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period in the previous year, the company posted $0.62 earnings per share. Boston Scientific’s revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.